FDA label update allows Rybelsus as a first-line type 2 diabetes treatment

On January 12, 2023, Novo Nordisk announced that the FDA approved a label update allowing Rybelsus (semaglutide) to be used as a first-line treatment for adults with type 2 diabetes, instead of only after other diabetes medicines had been tried ^[1][2].

Rybelsus is an oral GLP-1 receptor agonist. It was first approved on September 20, 2019, as the first oral GLP-1 medicine for adults with type 2 diabetes ^[1]. The tablet is taken once daily in the morning on an empty stomach ^[1]. Its approved uses are as an addition to diet and exercise to improve blood sugar control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for those events ^[1].

First-line means a medicine can be prescribed before other glucose-lowering drugs are tried. The announcement did not include the clinical trial results behind the change, the number of patients studied, or whether first-line use is limited to particular patients or doses; those details have not been disclosed in the record of the approval ^[1]. At the time, Rybelsus was available as 3 mg, 7 mg and 14 mg tablets ^[1].

Common side effects listed for Rybelsus, occurring in at least 5 percent of patients, are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation ^[1]. The label also carries warnings about acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, and pulmonary aspiration during general anesthesia or deep sedation ^[1].

Why it matters for patients

Before this label update, Rybelsus was positioned after another diabetes medicine had been tried. The change means an oral GLP-1 could be considered at the start of treatment for adults with type 2 diabetes, which can matter for people who prefer a daily pill over an injection ^[1].

The update applies to type 2 diabetes treatment, not to weight management. Wegovy is the semaglutide brand approved for weight reduction in obesity and overweight ^[1].

A label change is not the same as a coverage decision. Whether health plans will pay for Rybelsus as a first-line option has not been reported, and the approval record does not address cost or insurance ^[1]. The record also does not include data comparing Rybelsus with other first-line diabetes medicines, so no conclusion about which drug works better can be drawn from it ^[1].

What has changed since

The same approval record lists later actions on this product and related semaglutide medicines ^[1]:

• October 17, 2025: the FDA approved Rybelsus for cardiovascular risk reduction in adults with type 2 diabetes who are at high risk ^[1].
• December 9, 2024: a second Rybelsus formulation was approved, with 1.5 mg, 4 mg and 9 mg tablets ^[1].
• December 22, 2025: Wegovy tablets were approved at 1.5 mg, 4 mg, 9 mg and 25 mg for weight reduction and cardiovascular risk reduction in obesity or overweight ^[1].
• January 30, 2026: the FDA approved a labeling update renaming the Rybelsus second formulation as Ozempic (semaglutide) tablets ^[1].
• February 24, 2026: Novo Nordisk announced a reduction in the US list price for Wegovy, Ozempic and Rybelsus ^[1].

The record also lists a February 4, 2026 item stating that the Ozempic pill would be available in the United States in the second quarter of 2026 ^[1]. Dose selection and whether any of these changes affect first-line use for an individual patient are decisions for a prescriber; the approval record does not give dosing recommendations for first-line therapy ^[1].